Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Engage Grants Program

McMaster University

$25,000.00

Design and development of novel reactors for manufacturing PEGylated biopharmaceuticals

FY 2018-19

Summary
Life-saving protein biopharmaceuticals such as monoclonal antibodies and vaccines are increasingly being used*for a range of therapeutic applications. These are usually delivered in the form of injections. Formulating such*products is challenging due to major problems such as immunogenicity and short in-vivo half-life, and stability*issues such as susceptibility to degradation, chemical modification, denaturation and aggregation. Most of these*issues could be addressed by PEGylation which involves the covalent attachment of the synthetic polymer*polyethylene glycol (or PEG) to the protein molecule. BioVectra is a Prince Edward Island based company*with an established track record in manufacturing reagents used for protein PEGylation. However, current*PEGylation processes result in significant by-product synthesis, resulting in lower product recovery and*increased production cost. The proposed work addresses an urgent need expressed by our industrial partner,*BioVectra, i.e. improvement in efficiency of manufacturing PEGylated biopharmaceuticals. We propose to*address this challenge through the design and development of novel and efficient reactors for protein*PEGylation. We have a proven track record in designing and developing novel devices for conducting chemical*reactions and separations. The main attributes of the robust reactors developed in our group include superior*hydraulics, narrow residence time distribution, minimal back-mixing and uniform superficial velocities, all of*which will contribute towards increasing efficiency of protein PEGylation. Improvement in manufacturing*efficiency through the development of the novel reactor systems will increase product recovery, lower*manufacturing cost, and make the product safe for use. Consequently, life-saving medicine for the treatment of*serious diseases would become more affordable and accessible to the Canadian healthcare system. HQP trained*in this project would also be able to join the Canadian workforce and make valuable contributions to the*Canadian economy.
Program
Engage Grants Program
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
526374-2018
Name nom
Ghosh, Raja
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1802
Research subject group en
Chemical engineering
Research subject group fr
Génie chimique
Research subject en
Biochemical engineering
Research subject fr
Génie biochimique
Partie
1
Nb partie
1
Application title
Design and development of novel reactors for manufacturing PEGylated biopharmaceuticals
Keyword
NSERC
Application summary
Life-saving protein biopharmaceuticals such as monoclonal antibodies and vaccines are increasingly being used*for a range of therapeutic applications. These are usually delivered in the form of injections. Formulating such*products is challenging due to major problems such as immunogenicity and short in-vivo half-life, and stability*issues such as susceptibility to degradation, chemical modification, denaturation and aggregation. Most of these*issues could be addressed by PEGylation which involves the covalent attachment of the synthetic polymer*polyethylene glycol (or PEG) to the protein molecule. BioVectra is a Prince Edward Island based company*with an established track record in manufacturing reagents used for protein PEGylation. However, current*PEGylation processes result in significant by-product synthesis, resulting in lower product recovery and*increased production cost. The proposed work addresses an urgent need expressed by our industrial partner,*BioVectra, i.e. improvement in efficiency of manufacturing PEGylated biopharmaceuticals. We propose to*address this challenge through the design and development of novel and efficient reactors for protein*PEGylation. We have a proven track record in designing and developing novel devices for conducting chemical*reactions and separations. The main attributes of the robust reactors developed in our group include superior*hydraulics, narrow residence time distribution, minimal back-mixing and uniform superficial velocities, all of*which will contribute towards increasing efficiency of protein PEGylation. Improvement in manufacturing*efficiency through the development of the novel reactor systems will increase product recovery, lower*manufacturing cost, and make the product safe for use. Consequently, life-saving medicine for the treatment of*serious diseases would become more affordable and accessible to the Canadian healthcare system. HQP trained*in this project would also be able to join the Canadian workforce and make valuable contributions to the*Canadian economy.